From: Is rituximab effective for systemic sclerosis? A systematic review and meta-analysis
Author (year) | Country | Randomization | Sample (Total / RTX / Control) | Age (Min-Max/ Mean +/− SD) | Female sex (%) | Follow-up | RTX scheme | AE | Outcomes | Tomographic analysis | Jadad score | ||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sircar et al. (2018) | India | Yes | 60/ 30/ 30 | CG: 36.50 ± 9,73 RTX: 34.67 ± 8.13 | 83 | 6 months | Two RTX pulses of 1000 mg at 0 and 15 days i.v, and 1000 mg of RTX after 6 months as maintenance therapy | Yes | Skin - mRSS | Lung - FVC (%) | No | 3 | |||
Time | Control group | RTX group | Control group | RTX group | |||||||||||
Start | 23.83 ± 9.28 | 21.77 ± 9.86 | 59.25 ± 12.96 | 61.30 ± 11.28 | |||||||||||
6 months | 18.33 ± 7.69 (+) | 12.10 ± 10.14 (+) | 58.06 ± 111.23 | 67.52 ± 13.59 | |||||||||||
Boonstra et al. (2017) | Netherlands | Yes | 16/ 8/ 8 | CG: 36.6 ± 4.3 RTX: 44.5 ± 5.6 | 87.5 | 2 years | 1000 mg, two infusions, two weeks apart, and one 1000 mg RTX consolidation treatment once, after 6 months | Yes | Skin - mRSS | Lung - FVC (%) | Yes | 3 | |||
Time | Control group | RTX group | Control group | RTX group | |||||||||||
Start | 14.0 ± 3.8 | 16.4 ± 4.4 | 92.0 ± 6.1 | 97.9 ± 6.6 | |||||||||||
12 months (Δ) | - 1.8 | - 3.6 | + 0.3 | + 4.7 | |||||||||||
24 months (Δ) | - 1.9 | - 5.3 | - 1.4 | + 4.0 | |||||||||||
Daoussis et al. (2010) | Greece | Yes | 14/ 8/ 6 | CG: 47.7–68.5/ 56 RTX: 41.0–66.5/ 53 | 85.7 | 1 year | Two cycles of RTX. Each cycle consisted of four infusions of 375 mg per m2 of body area, once a week, repeated after 6 months | Yes | Skin - mRSS | Lung - FVC (%) | Yes | 3 | |||
Time | Control group | RTX group | Control group | RTX group | |||||||||||
Start | 11.5 ± 2.16 | 13.5 ± 6.9 | 86.0 ± 19.6 | 68.1 ± 19.7 | |||||||||||
12 months | 9.7 ± 3.4 | 8.4 ± 6.5 (+) | 81.7 ± 20.7 | 75.6 ± 19.7 (+) |